Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04244227 · ClinicalTrials.gov registry record · NA

Pilot Research on Opioid Use Disorder

A NA study of Opioid Use Disorder, sponsored by Theranova, L.L.C..

Active
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT04244227 is a NA study of Opioid Use Disorder that is active but no longer recruiting, run by Theranova, L.L.C.. The registered enrollment target is 10 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04244227, a NA study of Opioid Use Disorder, is active but no longer recruiting, sponsored by Theranova, L.L.C..

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the effects of peripheral nerve stimulation on opioid withdrawal, craving, and use in participants with opioid use disorder (OUD) who are initiating treatment with buprenorphine/naloxone. This is a pilot investigation in which participants will randomized (1:1) to the active or sham treatment.

Conditions Studied

Interventions

  • DEVICE Empower Neuromodulation System

Study Locations (1)

California

  • Northern California Institute for Research and Education - San Francisco

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-03-10
Est. Completion 2022-02-15
Phase NA

Sponsor

Theranova, L.L.C.

11 total trials

What the Registry Record Tells You About NCT04244227

The ClinicalTrials.gov registry entry for NCT04244227 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower). The listed sponsor is Theranova, L.L.C., which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Empower Neuromodulation System is the first listed.

NCT04244227 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04244227 about?

NCT04244227 is a clinical study titled "Pilot Research on Opioid Use Disorder". This study evaluates the effects of peripheral nerve stimulation on opioid withdrawal, craving, and use in participants with opioid use disorder (OUD) who are initiating treatment with buprenorphine/naloxone. This is a pilot investigation in which participants will randomized (1:1) to the active or ...

What is the current status of trial NCT04244227?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2020-03-10. Estimated completion is 2022-02-15.

What conditions does trial NCT04244227 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT04244227?

The interventions under investigation include: Empower Neuromodulation System (DEVICE).

Who is sponsoring clinical trial NCT04244227?

This trial is sponsored by Theranova, L.L.C., which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04244227 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.